FMRT Comment:
“NurExone has reached significant milestones towards improving the quality of life of millions of SCI patients and opening the door to novel therapies for other CNS traumatic indications. In addition to developing ExoTherapy, the company continues to support cutting-edge exosome-based research at top Israeli institutions. Although the exosome therapy market is in its early stages, the demand for non-invasive off-the-shelf drugs is continuing to rise, and R&D investments are increasing to advance its uses and raise awareness of its benefits. Positive Preliminary findings prove the company's potential and distinguish it as an emerging exosome leader with an intriguing biotechnology portfolio and strong partnerships. If the company is able to continue innovating and achieving meaningful milestones both in terms of partnerships and R&D, they are poised to become a leading biotech company and central player in both the exosome and the spinal cord treatment arenas."
Disclaimer: The author(s)/brand(s) is compensated to provide independent analysis of companies. Market commentary is individual opinion and should not serve as any form of advice. You must always do your own research. "Future Markets Research Tank" or any names, brands or accounts associated with it are digital brand names and do not seek to be any form of financial advisor or equity research organization. We may operate under a number of pseudonyms. We received monetary compensation for the content and thoughts presented above and that should be taken into account when reading any content presented. While our content generally focused on science, technology, and industry analysis, it may mention the public markets or companies that happen to be traded. It should be clear that our content is not investment advice. The stock market is volatile and investors are advised to do their own research prior to making a decision. Do Not Use Any Information in Our Publications, social media channels or anything else associate with our brand to Make an Investment Decision. There is no information on our website or distributed otherwise that should be used as the basis for an investment decision. We do not act, directly or indirectly, in the capacity of any of the following and you should not construe our activities as involving any of the following: (a) investment advisor; (b) broker dealer; (c) broker; (d) dealer; (e) stock recommender; (f) stock picker; (g) finder; (h) securities trading expert; (i) financial planner; (j) engaging in the offer and sale of securities; (k) securities analyst; (l) financial analyst; (m) providing price targets or buy or sell recommendations. Our activities may involve multiple potential and/or actual conflicts of interest - we may receive monetary or securities compensation in tied to the industries or companies we are we are researching. The third party shareholder from which we receive compensation also has an actual conflict of interest since he or she or it is paying us securities compensation for research services and such non-affiliate third party shareholder may sell other shares held while we are promoting the issuer that issues the stock held by such third party shareholder. There are no implied or express warranties regarding the contents of our Publications.
© Future Markets Research Tank (FMRT), all rights reserved.
DISCLAIMERSFollow us On TwitterDisclaimer: The author(s)/brand(s) is compensated to provide independent analysis of companies. Market commentary is individual opinion and should not serve as any form of advice. You must always do your own research. "Future Markets Research Tank" or any names, brands or accounts associated with it are digital brand names and do not seek to be any form of financial advisor or equity research organization. We may operate under a number of pseudonyms. We received monetary compensation for the content and thoughts presented above and that should be taken into account when reading any content presented. While our content generally focused on science, technology, and industry analysis, it may mention the public markets or companies that happen to be traded. It should be clear that our content is not investment advice. The stock market is volatile and investors are advised to do their own research prior to making a decision. Do Not Use Any Information in Our Publications, social media channels or anything else associate with our brand to Make an Investment Decision. There is no information on our website or distributed otherwise that should be used as the basis for an investment decision. We do not act, directly or indirectly, in the capacity of any of the following and you should not construe our activities as involving any of the following: (a) investment advisor; (b) broker dealer; (c) broker; (d) dealer; (e) stock recommender; (f) stock picker; (g) finder; (h) securities trading expert; (i) financial planner; (j) engaging in the offer and sale of securities; (k) securities analyst; (l) financial analyst; (m) providing price targets or buy or sell recommendations. Our activities may involve multiple potential and/or actual conflicts of interest - we may receive monetary or securities compensation in tied to the industries or companies we are we are researching. The third party shareholder from which we receive compensation also has an actual conflict of interest since he or she or it is paying us securities compensation for research services and such non-affiliate third party shareholder may sell other shares held while we are promoting the issuer that issues the stock held by such third party shareholder. There are no implied or express warranties regarding the contents of our Publications.